Insider Buy: Adicet Bio
6:54AM ET 12/13/2021 MT NewswiresAndrew Sinclair, Director, on December 08, 2021, executed a purchase for 500,000 shares in Adicet Bio (ACET) for $7,000,000. Following the Form 4 filing...
Quotes Snapshot > ACET
Adicet Bio Inc ACET:NASDAQ
Last Price$12.99NASDAQ Closing Price as of 4:00PM ET 1/24/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+1.06(8.89%)
Bid (Size)$12.00 (2)
Ask (Size)$13.00 (3)
Day Low / High$11.13 - 13.07
Volume404.3 K
Read more news Recent News
Adicet Bio Closes $100.6 Million Common Stock Offering
4:10PM ET 12/10/2021 MT NewswiresAdicet Bio (ACET) said late Friday it closed its public offering of about 7.19 million common shares at $14 each, raising $100.6 million in gross proceeds....
Adicet Bio Prices Common Stock Offering at $14 Per Share
3:18AM ET 12/08/2021 MT NewswiresAdicet Bio (ACET) on Wednesday priced a public offering of about 6.3 million common shares at $14 per share for expected gross proceeds of $87.5 million....
Adicet Bio Commences Common Stock Offering
4:30PM ET 12/07/2021 MT NewswiresAdicet Bio (ACET) said late Tuesday it has launched a public offering of an undisclosed amount its common shares. The biotechnology company plans to grant...
View all Commentary and Analysis
Adicet Bio (ACET) Investor Presentation - Slideshow
10:23AM ET 8/13/2021 Seeking AlphaWeek 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge
7:08AM ET 4/25/2021 Seeking AlphaLAVA Therapeutics Seeks $101 Million U.S. IPO
1:30PM ET 3/22/2021 Seeking AlphaAdicet Bio (ACET) Investor Presentation - Slideshow
4:27AM ET 2/28/2021 Seeking AlphaCompany Profile
Business DescriptionAdicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. View company web site for more details
| Address | 500 Boylston Street Boston, Massachusetts 02116 |
| Phone | +1.857.315.5528 |
| Number of Employees | N/A |
| Recent SEC Filing | 01/11/2022 4 |
| President, CEO, Secretary & Director | Chen Schor |
| Chief Financial Officer | Brian Nicholas Harvey |
| Chief Medical Officer & Senior Vice President | Francesco Galimi |
| Chief Technology Officer | Donald Healey |
Company Highlights
| Price Open | $11.87 |
| Previous Close | $11.93 |
| 52 Week Range | $6.25 - 18.49 |
| Market Capitalization | $415.1 M |
| Shares Outstanding | 32.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.05 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -570.14% |
| Return on Equity | -27.86% |
Analyst Ratings as of 05/17/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |